Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi (MGX) Accumulated Expenses (2023 - 2025)

Metagenomi (MGX) has disclosed Accumulated Expenses for 3 consecutive years, with $848000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses fell 47.82% to $848000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $848000.0, a 47.82% decrease, with the full-year FY2025 number at $848000.0, down 47.82% from a year prior.
  • Accumulated Expenses was $848000.0 for Q4 2025 at Metagenomi, down from $3.9 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $11.5 million in Q4 2023 to a low of $848000.0 in Q4 2025.
  • A 3-year average of $6.3 million and a median of $6.1 million in 2025 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: crashed 85.84% in 2024, then decreased 13.55% in 2025.
  • Metagenomi's Accumulated Expenses stood at $11.5 million in 2023, then plummeted by 85.84% to $1.6 million in 2024, then plummeted by 47.82% to $848000.0 in 2025.
  • Per Business Quant, the three most recent readings for MGX's Accumulated Expenses are $848000.0 (Q4 2025), $3.9 million (Q3 2025), and $5.9 million (Q2 2025).